. Initial vaccinations at months zero G(NJ) proteins just as in the larger study described below indicating that boosting was effective (data not and two were performed with a live attenuated VSV recombinant expressing a hybrid HIV envelope protein shown). We also detected a transient neutralizing antibody titer (1:40) to HIV Env 89.6 in AR88 but not in AR89, (89.6) with its cytoplasmic domain replaced with the VSV G protein cytoplasmic domain (Johnson et al., 1997).
but the neutralizing antibody was not detectable at the time of challenge, two months after the last boost. These vaccinations were given by a combination of intramuscular and oral routes. Although neutralizing antibody responses to VSV and total antibody to Env were CD8 ؉ T Cell Responses The HIV-specific CD8 ϩ T cell responses were analyzed detected by ELISA after the vaccination and boost, we did not detect HIV neutralizing antibody (data not shown). these counts remained at or near zero until the animals developed AIDS at days 148 and 155. The viral loads in both controls were Ͼ10 8 /ml at day 14 after challenge controls challenged intravenously with SHIV 89.6P at but then declined to 10 5 -10 6 /ml after the CD4 ϩ T cell three months following the last boost and two vaccinees population was largely eliminated. In contrast, the two and three controls challenged at six months following vaccinees showed only a moderate initial drop in CD4 ϩ the last boost. T cell counts which recovered to above 600/l. The initial We determined that all vaccinations and boosts were viral loads in the vaccinees were 1-2 logs lower than in successful because neutralizing titers to the three VSV the controls, and declined to below detection (less than glycoproteins were detected in all five vaccinees (Figure 500 copies/ml) in AR88 by day 42 and to 3 ϫ 10 3 in 3B). The responses to the first vector (GI) were generally AR89. Initially we were able to culture challenge virus the strongest, with reduced titers observed to the GCh from both animals, but after the load fell to undetectable and GNJ vectors, although there was substantial variain AR88, we were not able to recover virus by coculture tion among animals. A similar pattern of reduced rewith fresh PBMC. This animal appears to have cleared sponses to subsequent vectors was observed prethe infection. Both vaccinees have remained healthy for viously in mice inoculated sequentially with the same over 14 months after challenge.
vectors and is likely due to reduction of vector replication by cytotoxic T cells.
Larger Study Involving 11 Rhesus Macaques
To attempt to obtain statistical significance in our results, we performed a larger study. We also used a more Antibody to Oligomeric gp140 and HIV Neutralizing Antibody compressed time frame for an initial vaccination and two boosts. The final boost at day 120 raised the ELISA titers only 1998). Neutralizing antibody to HIV 89.6 was present in all The intravenous challenges with SHIV 89.6P were performed either three or six months after the last boost as animals at day 14 after challenge, peaked at day 28, and generally declined thereafter ( Figure 4C ). In contrast, indicated in Figure 3A . We measured the total antibody responses to oligomeric Env gp140 by ELISA and the neutralizing antibody to the challenge virus did not appear until day 28 but then increased until at least day appearance of neutralizing antibody to both HIV 89.6 (Env in vaccine) and to 89.6P (Env in challenge) in all 90 ( Figure 4E ). The two control animals, JO38 and N318, that showed some ELISA titer to gp140, also showed vaccinees and all controls (Figure 4) . The ELISA titers in all vaccinees showed large increases at day 28 after some neutralizing antibody to the challenge virus but not until day 42 ( Figure 4F ). The neutralizing antibody challenge, ranging between 38,000 and 90,000 in all animals. These then declined to between 12,000 and to 89.6P appeared two weeks earlier in the vaccinees compared with the two controls that responded ( titer increased to an extremely high level of 39,000 in (MHC) class I allele Mamu-A*01. We measured vaccineelicited CTL responses specific for the immunodominant the JO38 control at day 90 and a low level of cross neutralization of 89.6 was seen also (Figures 4F and 4D) . ϩ T cell responses after control AN98) we were not able to detect CTL responses to the p11C, C-M epitope before or after challenge (not the first boost, but no augmentation of CD8 ϩ T cell responses was evident after the second boost. After chalshown). Because of the small number of cells available from these animals, we were not able to repeat a comlenge, the vaccinees previously immunized with VSV constructs mounted rapid and vigorous virus-specific plete analysis of their responses by ELISPOT. However, further analyses of some time points after challenge CD8 ϩ T cell responses, with the exception of animal I578, in which there was a high background of IFN-␥ revealed that the vaccinee AJ73 made responses of greater than 200 SFC/10 6 PBMC to both Env and Gag, production in the ELISPOT assay. K510 and I633 had very strong responses, as high as 1000 SFC/10 6 PBMC. while the responses from the AN98 control were at least 10-fold lower (not shown). K510 made a strong Env-specific response, but a lower Gag response. Of the control group, some animals made no or a very low response (G742, AP05), while others CD4 ؉ T Cell Counts, Viral Loads, and Clinical Events after Challenge (JO38, N318, and AV72) showed moderate increases after challenge.
After intravenous challenge with SHIV89.6P, we followed CD4 ϩ T cell counts, viral loads, and clinical events in all Two of the five vaccinees (AK17 and AJ73) and two of the five controls (APO5 and AN98) were reported animals. Figure 6A shows that all controls suffered a severe drop in CD4 ϩ T cell counts to below 100/l by to be positive for the major histocompatibility complex day 28 after challenge. CD4 ϩ T cell counts in four of the contrast the vaccinees generally had lower viral loads than the controls initially and these fell to undetectable controls remained at low levels until they developed AIDS between days 43 and 171 after challenge. Two of (I578 and AK17) or were between 10 3 and 10 4 /ml. The clinical events noted in the control animals inthe six controls showed a partial recovery in CD4 ϩ T cells to about 200/l but then fell to below 100/l by cluded anorexia, severe weight loss, muscle wasting, diarrhea, severe lymphoid depletion, retroviral pneumoday 180 and one of these later developed AIDS. In contrast, the vaccinees generally showed a significant drop nia, SIV giant cells in lungs, cytomegaloviral pneumonia, and glomerulosclerosis. in CD4 ϩ T cell numbers after challenge, but recovered and have maintained counts averaging over 400/l for up to nine months after challenge ( Figure 6B Viral RNA measurements in the controls ( Figure 6C ) detectable clinical symptoms. Animals were examined daily for two weeks after vaccination. They did not did were consistent with the CD4 ϩ T cell counts. The four animals that progressed to AIDS most rapidly had very not exhibit fever, vesicular lesions, or inflammation of the mouth or throat after oral vaccination. There was no high initial viral loads of ‫01ف‬ 8 /ml that dropped coincident with CD4 ϩ T cell loss, but rebounded to ‫01ف‬ 6 /ml before inflammation of the nose after intranasal vaccination.
Intramuscular vaccination was not associated with inthe animals progressed to AIDS. The two control animals that maintained low CD4
ϩ T cell counts had much lower flammation or edema. Complete blood counts were normal in all animals, behavior including eating was normal, viral loads, although the one animal with an undetectable viral load (N318) still progressed to AIDS by day 275. In and the animals gained weight. We also attempted to In the pilot study, animal AR88 had stronger CTL responses to Env and Gag than did AR89, and controlled viral load more effectively than did AR89. AR88 also had Discussion stronger total antibody responses including neutralizing antibody, than did AR89. In the larger study, the vacStatistically Significant Protection from AIDS Combining the results of our two studies, it is clear that cinee I578, showing the best preservation of CD4 ϩ T cell numbers and elimination of viral load to below detection, vaccination with VSV recombinants expressing Env and Gag proteins provides highly significant protection from had the lowest initial CTL responses after challenge, although the responses were sustained. This animal was AIDS (p ϭ 0.001 by a two-sided Fisher exact test). Seven of seven vaccinees have remained disease free. The two intermediate in total antibody and neutralizing antibody production. Other vaccinees with notably high CTL acvaccinees in the pilot study have remained healthy for more than 14 months after challenge, and the vaccinees tivity (I633 and K510) controlled challenge virus replication well, but also made good antibody responses. The in the second study have remained healthy for 11 months (early challenge group) or seven months (later general correlation of both humoral and cellular immune responses in vaccinated animals makes it impossible challenge group). In contrast, seven of eight control animals progressed to AIDS with an average time of 148 to conclude that one response is more important than the other in long-term control of viral replication. Howdays (Figure 7) . The protection from AIDS correlated with large differences in peak viral loads (averaging ever, the early suppression of challenge virus replication by day 28 in all animals is presumably due to CTL activity greater than 10-fold higher in controls versus vaccinees), macaques using a VSV vector encoding an influenza hemagglutinin protein (VSV-HA) indicates that the intranasal route alone is sufficient to induce strong neutralizing antibody to both VSV and influenza virus. It appears better than oral inoculation and as effective as intranasal combined with intramuscular vaccination (N.R., A.L., P.M., A.R., and J.R., unpublished results). We therefore plan to test this single mucosal vaccination route for protection against AIDS in macaques. An AIDS vaccine that could be given intranasally in drop or spray form would be much easier to deliver on a global scale than one requiring multiple injections. It is also important to point out that there is no guarantee that the results from the monkey model, using a virus that is only partially derived from HIV, will be predictive of results in humans. particles given intranasally induce immune responses Among the control animals, there were two, JO38 and equivalent to those generated with 10 5 infectious parti-N318, that managed to control viral load and preserve cles because the vector replicates (Roberts et al., 1998, significant levels of CD4 ϩ T cells after challenge. These 1999). If the results from mice apply to primates, it might animals also made higher and more sustained CTL rebe possible to produce sufficient AIDS vaccine for more sponses than the other controls. They also made total than one billion people starting from one liter of supernaanti-Env antibody by day 28, and neutralizing antibody tant from VSV vector-infected cells. by day 42. Interestingly, the one control animal, J038, We do not know why the VSV vectors are able to that has not yet developed AIDS produced a phenomegenerate such strong immune responses, but it likely nally high neutralizing antibody titer to the challenge relates to the very high level of intracellular synthesis of virus (1:39,000). This is a higher neutralizing titer than antigens in infected cells. In addition, VSV itself encodes has been observed previously to SHIV 89.6P and may only five proteins of its own to compete in the immune contribute to the survival of this animal. However, as response to the HIV proteins. In direct vector compariin the vaccinees, the early control of challenge virus sons in mice, we find that the humoral and cellular imreplication by day 28 in JO38 and N318 correlates well mune responses to HIV Env expressed by VSV are 6-10 with peak CTL activity when neutralizing antibody is not fold greater than those generated by vaccinia virus yet present. expressing the same HIV Env (K. Haglund, N.R., and J.R., unpublished observations). Vaccinia encodes about 200 Potential for a Human AIDS Vaccine Based proteins of its own that are presumably competing for on Attenuated VSV Recombinants a limited immune response capability. In addition, the Based on the experiments reported here, we think it is ability to exchange the VSV envelope G proteins and likely that VSV recombinants expressing HIV gag and escape the neutralizing antibody response to the vector env genes could be an effective AIDS vaccine in humans, allows major boosting of immune responses. Another especially if the boosting system using a vector with a major advantage of VSV vectors is that they are replicaheterologous VSV G protein were employed. Here we tion competent and carry out limited replication and used two different boosting vectors, but the majority of spread until they are eliminated by nonadaptive and the boosting, at least for antibody responses, occurred adaptive immune responses. Because the virus repliafter the first boost. Therefore, it will be important to cates entirely in the cytoplasm from only RNA intermedidetermine if a single vaccination or single vaccination ates, there are no concerns about persistence through and one boost can confer equivalent protection in the integration host DNA or damage of host DNA. macaque model
The route of vaccination is also an important issue to address. The ease of delivery of an AIDS vaccine will Safety With any live virus vector, vector-associated pathogenelikely be key to stemming the worldwide AIDS epidemic. In this study we employed a combination of oral and sis is of critical concern. In young mice, wild-type VSV given intranasally enters the brain via the olfactory bulb intramuscular, or intranasal and intramuscular routes for vaccination and boosting. This protocol would be and can cause encephalitis (Reiss et al., 1998) . However the VSV recombinants derived from plasmid DNA are cumbersome for mass vaccination of humans because injection would be required. However, recent testing in sufficiently attenuated that they do not cause encephali- hr on BHK cells in serum-free DME medium followed by centrifuga-GAGAG with an underlined NheI cloning site. The PCR product was tion to remove cell debris. The titers of viruses obtained in the cloned into the unique XhoI and NheI sites of the following three absence of serum were reduced 3-to 5-fold compared to those vectors, pVSV(GI) XN-1, pVSV(GNJ) XN-1, or pVSV(GCh) XN-1 which obtained in the presence of serum. Virus samples were frozen at were then used to recover each of the VSV recombinants expressing Ϫ80ЊC and titers ranged from 2 ϫ 10 7 to 10 8 pfu/ml after thawing. Gag. Methods of recovery were as described previously (Rose et Virus for inoculation of macaques was diluted to a concentration of al., 2000).
2 ϫ 10 7 pfu/ml with DME if necessary. Macaques were inoculated with a total of 1.0 ml (2 ϫ 10 7 pfu) of each construct. Intramuscular Elisa Assay for Total Antibody to Oligomeric HIV Env injections were with 0.6 ml virus and intranasal or oral vaccinations ELISA assays were performed essentially as described previously (Richardson et al., 1996; Rose et al., 2000) . Costar 96-well ELISA of 0.4 ml were delivered with a syringe without a needle. plates were first coated with 0.1 mg/ml of concanavalin A (ConA, Sigma) in 20 mM Tris-HCl, 1 M NaCl, pH 8.5 for 2 hr at room tempera-ELISPOT Assay ture. In the next step gp140 diluted in PBS was added. After the The ELISPOT assay using recombinant vaccinia viruses (rVV) was binding of gp140 to ConA overnight at 4ЊC, a blocking step with performed as previously described (Moretto et al., 2000) . Cryopre-PBS containing 10% calf serum (blocking solution) was carried out served PBMC were thawed and washed three times in medium plus for 30 min. Each monkey serum sample was diluted 2-fold with 15% fetal calf serum. 2 ϫ 10 5 PBMCs were resuspended in 200 l blocking solution from 1:100 up to 1:102,400 and was added to the of medium plus 15% fetal calf serum and added to the wells of a wells. Plates were incubated at room temperature for 2 hr. The microtiter plate. PBMCs were then infected, at a multiplicity of infecsecondary antibody, horseradish peroxidase-conjugated goat antition of 2, with rVV expressing HIV envelope, SIV gag, control vaccinia human (Pierce), was added to the incubation at a final dilution of (TkϪ), or phytohemagglutinin as positive control for 16 hr at 37ЊC. 1:20,000 and the plates were incubated for 1.5 hr at room temperaPBMCs were transferred to a microtiter plate (U-CyTech, Utrecht, ture. The substrate used for colorimetric analysis was 2,2Ј-AziThe Netherlands) coated with monoclonal antibody specific for rhenobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt tabsus IFN-␥. After a 5 hr incubation at 37ЊC, PBMCs were removed lets, 10 mg/tablet (Immunopure ABTS, Pierce). Following each by washing with phosphate-buffered saline ϩ 0.05% Tween. The incubation step, wells were washed three times with 200 l PBSwells were filled with an appropriate dilution of a biotinylated detec-0.05% Tween-20. Following conjugate incubation, a single 2ϫ PBStor antibody and incubated for 1 hr at 37ЊC. After incubation the 0.05% Tween high salt wash was performed to lower background wells were washed with phosphate-buffered saline ϩ 0.05% Tween binding. This wash was followed by three washes with 1ϫ PBSand incubated with a goat anti-biotin antibody solution for 1 hr at 0.05% Tween-20 wash solution. The volume added to the wells in 37ЊC. The wells were then washed with phosphate-buffered saline ϩ each step was 100 l except for the blocking step, where a volume 0.05% Tween, and filled with a chromogenic substrate. After color of 200 l/well was added. All incubations except the binding of development, spots were visualized by light microscopy and adgp140 were carried out at room temperature. Optical densities were justed to spot forming cells/10 6 PBMC. determined at a wavelength of 405 nm in a BioRad ELISA plate reader. Titers were determined from graphs of the data and are Cytokine Flow Cytometry given as the reciprocal of the serum dilution that gave an absorbance 
